biotechnology

Biotech Adam Feuerstein

A Celldex treatment induces symptom relief in patients with chronic hives

Pharmalot Ed Silverman

The near-term outlook for pharma industry earnings just got a little worse

Biotech Matthew Herper

New analysis of Amarin’s Vascepa resurrects big questions about effectiveness

In the Lab Akila Muthukumar

Lattes and gummies: Food science inspires a new approach to treating gut and liver injury

Biotech Matthew Herper

ARCH Venture Partners raises $3 billion fund to invest in biotech startups despite brutal stock downturn

Pharmalot Ed Silverman

Pharmalittle: Sarepta halts a Duchenne clinical trial over safety; Why the CVS Health whistleblower lawsuit comes at a pivotal moment

Biotech Adam Feuerstein

FDA halts study of Sarepta treatment for Duchenne muscular dystrophy due to safety concern

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Juul’s doomsday, Merck’s buyout plans, & the next Theranos verdict

Adam's Take Adam Feuerstein

A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser

Biotech Matthew Herper

Uniqure’s Huntington’s gene therapy lowers key protein in small trial

Biotech Allison DeAngelis

With cryptocurrency and NFTs, ‘decentralized science’ seeks to upend drug industry financing

Biotech Ryan Cross — The Boston Globe

Startup will target cystic fibrosis with a new twist on gene therapy

Biotech Adam Feuerstein

PTC’s Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

Pharmalot Ed Silverman

Pharmalittle: Merck is eyeing Seagen to beef up its cancer drug portfolio; Lawmakers want GAO to probe PBMs

The Readout LOUD Adam Feuerstein, Meg Tirrell and Damian Garde

A longtime investor talks interest rates, biotech, and why luxury cars are a warning sign

The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: Paul Offit on Covid vaccines for kids, plus: how the Fed affects biotech, & another Alzheimer’s setback

Pharma Adam Feuerstein

A Roche treatment fails to slow cognitive decline in patients with inherited form of Alzheimer’s disease

Biotech Allison DeAngelis

Third Rock Ventures plots next chapter after raising $1.1 billion fund

Adam's Take Adam Feuerstein

Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen

Biotech Jonathan Wosen and Akila Muthukumar

Eli Lilly wins FDA approval for first-ever treatment for hair loss caused by autoimmunity

Biotech Jason Mast

In early trial, drug shrinks tumors in majority of children with most common form of brain cancer

Biotech Adam Feuerstein

Canada approves ALS drug from Amylyx Pharma as U.S. patients await extended review

Biotech Jonathan Wosen

Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve

Biotech Adam Feuerstein

Updated study results show a CRISPR treatment for blood diseases continues to benefit patients

Biotech Damian Garde

FDA advisers endorse Bluebird gene therapy for rare blood disorder

Biotech Damian Garde

FDA advisers unanimously endorse Bluebird’s gene therapy for rare disorder

Biotech Allison DeAngelis

Biospring Partners closes $245 million first fund as private markets tense up

Biotech Matthew Herper

Watch: An interview with the FDA’s top cancer regulator

Biotech Damian Garde

Praxis’ novel antidepressant fails make-or-break trial